A randomized blind trial of Iopamidol and meglumine calcium metrizoate (Triosil 280, Isopaque Cerebral) in cerebral angiography
- 1 February 1982
- journal article
- research article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 55 (650) , 117-119
- https://doi.org/10.1259/0007-1285-55-650-117
Abstract
A randomized blind trial of Iopamidol and meglumine calcium metrizoate (Triosil 280, Isopaque Cerebral) for cerebral angiography was performed in 30 patients. The Iopamidol was better tolerated and caused significantly less discomfort in patients than metrizoate. There was no difference in the quality of the radiographs. A further 13 patients also received Iopamidol for cerebral angiography with similar results. No adverse effects were observed in any of the patients. Iopamidol apparently has significant advantages over currently available contrast media for cerebral angiography.This publication has 9 references indexed in Scilit:
- A clinical trial of a new low osmolality contrast mediumThe British Journal of Radiology, 1979
- Cardiovascular Effects Induced by the Injection of a New Nonionic Contrast Medium (Iopamidol): Experimental Study in DogsInvestigative Radiology, 1979
- The Blood-Brain Barrier: Effects of Nonionic Contrast Media with and without Addition of Ca2+and Mg2+Investigative Radiology, 1979
- Clinical testing of amipaque for cerebral angiographyNeuroradiology, 1978
- Equi-Osmolal Opening of the Blood-Brain Barrier in the Rabbit by Different Contrast MediaActa Radiologica. Diagnosis, 1974
- Local Toxicity of Metrizamide on Intravascular InjectionActa Radiologica. Diagnosis, 1973
- Neurotoxicity of Roentgen Contrast MediaActa Radiologica. Diagnosis, 1970
- Blood-Brain Barrier Changes Associated with Unilateral Cerebral AngiographyInvestigative Radiology, 1966
- Technique for the pharmaco-dynamic investigation of contrast media for cerebral angiographyActa Radiologica, 1956